Detection and Characterization of Disseminated Tumor Cells present in Bone Marrow of Cancer Patients

  • Sabine Riethdorf
  • Volkmar Müller
  • Catherine Alix-Panabières
  • Klaus Pantel
Chapter
First Online:
Part of the Topics in Bone Biology book series (TBB, volume 5)

Abstract

Early tumor cell dissemination occurs even in patients with small solid tumors, and bone marrow (BM) is a common homing organ for blood-borne disseminated tumor cells (DTCs) derived from primary tumors. Immunocytochemical or molecular assays allow the detection of a single DTC in BM at a frequency of one tumor cell in one million surrounding hematopoietic cells; e.g., tumor cells are frequently detected in the BM of breast cancer patients without clinical or even histopathologic signs of metastasis. Evidence has emerged that the detection of DTCs and circulating tumor cells (CTCs) in blood may provide important prognostic information and, in addition, might help to monitor efficacy of therapy.

Keywords

Bone Marrow Breast Cancer Patient Prostate Cancer Patient Tumor Stem Cell CK19 mRNA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846.PubMedCrossRefGoogle Scholar
  2. 2.
    Alix-Panabieres C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, Choquet-Kastylevsky G, Vendrell JP (2005) Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 299:177–188.PubMedCrossRefGoogle Scholar
  3. 3.
    Alix-Panabieres C, Muller V, Pantel K (2007) Current status in human breast cancer micrometastasis. Curr Opin Oncol 19:558–563.PubMedCrossRefGoogle Scholar
  4. 4.
    Alix-Panabieres C, Rebillard X, Brouillet JP, Barbotte E, Iborra F, Segui B, Maudelonde T, Jolivet-Reynaud C, Vendrell JP (2005) Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem 51:1538–1541.PubMedCrossRefGoogle Scholar
  5. 5.
    Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V, Fabbro M, Pantel K (2007) Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 53: 537–539.PubMedCrossRefGoogle Scholar
  6. 6.
    Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12: 5615–5621.PubMedCrossRefGoogle Scholar
  7. 7.
    Bauer KD, de la Torre-Bueno J, Diel IJ, Hawes D, Decker WJ, Priddy C, Bossy B, Ludmann S, Yamamoto K, Masih AS, Espinoza FP, Harrington DS (2000) Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 6:3552–3559.PubMedGoogle Scholar
  8. 8.
    Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T (2006) Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat 97:91–96.PubMedCrossRefGoogle Scholar
  9. 9.
    Becker S, Solomayer E, Becker-Pergola G, Wallwiener D, Fehm T (2007) Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 106:239–243.PubMedCrossRefGoogle Scholar
  10. 10.
    Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S, Van Marck E, Vermeulen PB, Dirix LY (2006) Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. Clin Breast Cancer 7:146–152.PubMedCrossRefGoogle Scholar
  11. 11.
    Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S, Van Marck E, Vermeulen PB, Dirix LY (2006) Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 94: 672–680.PubMedGoogle Scholar
  12. 12.
    Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418:823.PubMedCrossRefGoogle Scholar
  13. 13.
    Borgen E, Naume B, Nesland JM, Nowels KW, Pavlak N, Ravkin I, Goldbard S (2001) Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples. Cytometry 46:215–221.PubMedCrossRefGoogle Scholar
  14. 14.
    Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, Schlichting E, Qvist H, Naume B (1998) Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 185:427–434.PubMedCrossRefGoogle Scholar
  15. 15.
    Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer E, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau J-P, Garcia J, Pantel K (1999) Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1:377–388.PubMedCrossRefGoogle Scholar
  16. 16.
    Braun S, Pantel K (1995) Immunodiagnosis and immunotherapy of isolated tumor cells disseminated to bone marrow of patients with colorectal cancer. Tumori 81:78–83.PubMedGoogle Scholar
  17. 17.
    Braun S, Pantel K (1999) Micrometastatic bone marrow involvement: detection and prognostic significance. Med Oncol 16:154–165.PubMedCrossRefGoogle Scholar
  18. 18.
    Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL (1999) Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 5:3999–4004.PubMedGoogle Scholar
  19. 19.
    Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18:80–86.PubMedGoogle Scholar
  20. 20.
    Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533.PubMedCrossRefGoogle Scholar
  21. 21.
    Braun S, Schindlbeck C, Hepp F, Janni W, Kentenich C, Riethmuller G, Pantel K (2001) Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol 19:368–375.PubMedGoogle Scholar
  22. 22.
    Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K (2001) ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I–III breast cancer patients. Cancer Res 61:1890–1895.PubMedGoogle Scholar
  23. 23.
    Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793–802.PubMedCrossRefGoogle Scholar
  24. 24.
    Calaluce R, Miedema BW, Yesus YW (1998) Micrometastasis in colorectal carcinoma: a review. J Surg Oncol 67:194–202.PubMedCrossRefGoogle Scholar
  25. 25.
    Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67:1979–1987.PubMedCrossRefGoogle Scholar
  26. 26.
    Choesmel V, Anract P, Hoifodt H, Thiery JP, Blin N (2004) A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases. Cancer 101:693–703.PubMedCrossRefGoogle Scholar
  27. 27.
    Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40:403–439.PubMedCrossRefGoogle Scholar
  28. 28.
    Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP (1991) Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9:1749–1756.PubMedGoogle Scholar
  29. 29.
    Crawford NP, Hunter KW (2006) New perspectives on hereditary influences in metastatic progression. Trends Genet 22:555–561.PubMedCrossRefGoogle Scholar
  30. 30.
    Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791.PubMedCrossRefGoogle Scholar
  31. 31.
    Czerkinsky CC, Svennerholm AM (1983) Ganglioside GM1 enzyme-linked immunospot assay for simple identification of heat-labile enterotoxin-producing Escherichia coli. J Clin Microbiol 17:965–969.PubMedGoogle Scholar
  32. 32.
    Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS (1994) Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12:475–482.PubMedGoogle Scholar
  33. 33.
    Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284.PubMedCrossRefGoogle Scholar
  34. 34.
    Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652–1658.PubMedCrossRefGoogle Scholar
  35. 35.
    Farnie G, Clarke RB (2007) Mammary stem cells and breast cancer – role of Notch signalling. Stem Cell Rev 3:169–175.PubMedCrossRefGoogle Scholar
  36. 36.
    Fehm T, Becker S, Bachmann C, Beck V, Gebauer G, Banys M, Wallwiener D, Solomayer EF (2006) Detection of disseminated tumor cells in patients with gynecological cancers. Gynecol Oncol 103:942–947.PubMedCrossRefGoogle Scholar
  37. 37.
    Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E (2006) A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107: 885–892.PubMedCrossRefGoogle Scholar
  38. 38.
    Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J (2002) Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8:2073–2084.PubMedGoogle Scholar
  39. 39.
    Fillmore C, Kuperwasser C (2007) Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 9:303.PubMedCrossRefGoogle Scholar
  40. 40.
    Gangnus R, Langer S, Breit E, Pantel K, Speicher MR (2004) Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res 10:3457–3464.PubMedCrossRefGoogle Scholar
  41. 41.
    Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921–930.PubMedCrossRefGoogle Scholar
  42. 42.
    Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W (2001) Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 19:3669–3674.PubMedGoogle Scholar
  43. 43.
    Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G, Friese K (2001) Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 19:960–971.PubMedGoogle Scholar
  44. 44.
    Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquernier J, Viens P, Kleer C, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567.PubMedCrossRefGoogle Scholar
  45. 45.
    Gudjonsson T, Villadsen R, Nielsen HL, Ronnov-Jessen L, Bissell MJ, Petersen OW (2002) Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev 16:693–706.PubMedCrossRefGoogle Scholar
  46. 46.
    Haraguchi N, Inoue H, Tanaka F, Mimori K, Utsunomiya T, Sasaki A, Mori M (2006) Cancer stem cells in human gastrointestinal cancers. Hum Cell 19:24–29.PubMedCrossRefGoogle Scholar
  47. 47.
    Harbeck N, Untch M, Pache L, Eiermann W (1994) Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 69:566–571.PubMedCrossRefGoogle Scholar
  48. 48.
    Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:4218–4224.PubMedCrossRefGoogle Scholar
  49. 49.
    Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW (1995) Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1: 1035–1039.PubMedCrossRefGoogle Scholar
  50. 50.
    Hemsen A, Riethdorf L, Brunner N, Berger J, Ebel S, Thomssen C, Janicke F, Pantel K (2003) Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer 107: 903–909.PubMedCrossRefGoogle Scholar
  51. 51.
    Ho JJ, Norton K, Chung YS, Kim YS (1993) Expression of CA19–9, DU-PAN-2, and SPan-1 antigens on two types of normal salivary mucins. Oncol Res 5:347–356.PubMedGoogle Scholar
  52. 52.
    Hofmann T, Buchner A, Hofstetter A, Stief CG, Oberneder R, Riesenberg R (2007) Prognostic relevance of disseminated tumour cells in bone marrow of patients with transitional cell carcinoma. Eur J Cancer 43:2678–2684.PubMedCrossRefGoogle Scholar
  53. 53.
    Hunter K (2006) Host genetics influence tumour metastasis. Nat Rev Cancer 6:141–146.PubMedCrossRefGoogle Scholar
  54. 54.
    Hunter KW, Crawford NP (2006) Germ line polymorphism in metastatic progression. Cancer Res 66:1251–1254.PubMedCrossRefGoogle Scholar
  55. 55.
    Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D (2007) Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25:5194–5202.PubMedCrossRefGoogle Scholar
  56. 56.
    Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K (2005) The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103:884–891.PubMedCrossRefGoogle Scholar
  57. 57.
    Jung R, Kruger W, Hosch S, Holweg M, Kroger N, Gutensohn K, Wagener C, Neumaier M, Zander AR (1998) Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer 78:1194–1198.PubMedCrossRefGoogle Scholar
  58. 58.
    Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A, Neumaier M (1999) Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer 81:870–873.PubMedCrossRefGoogle Scholar
  59. 59.
    Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR (2005) Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97:1840–1847.PubMedCrossRefGoogle Scholar
  60. 60.
    Kallergi G, Mavroudis D, Georgoulias V, Stournaras C (2007) Phosphorylation of FAK, PI-3 K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 13:79–88.PubMedCrossRefGoogle Scholar
  61. 61.
    Kang Y, Massague J (2004) Epithelial–mesenchymal transitions: twist in development and metastasis. Cell 118:277–279.PubMedCrossRefGoogle Scholar
  62. 62.
    Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmuller G (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360:683–689.PubMedCrossRefGoogle Scholar
  63. 63.
    Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA, Riethmuller G (2002) Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 20:387–392.PubMedCrossRefGoogle Scholar
  64. 64.
    Kowalewska M, Chechlinska M, Markowicz S, Kober P, Nowak R (2006) The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. Eur J Cancer 42:2671–2674.PubMedCrossRefGoogle Scholar
  65. 65.
    Kraeft SK, Sutherland R, Gravelin L, Hu GH, Ferland LH, Richardson P, Elias A, Chen LB (2000) Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res 6:434–442.PubMedGoogle Scholar
  66. 66.
    Kraeft SK, Ladanyi A, Galiger K, Herlitz A, Sher AC, Bergsrud DE, Even G, Brunelle S, Harris L, Salgia R, Dahl T, Kesterson J, Chen LB (2004) Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res 10:3020–3028.PubMedCrossRefGoogle Scholar
  67. 67.
    Kufer P, Zippelius A, Lutterbuse R, Mecklenburg I, Enzmann T, Montag A, Weckermann D, Passlick B, Prang N, Reichardt P, Dugas M, Kollermann MW, Pantel K, Riethmuller G (2002) Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 62:251–261.PubMedGoogle Scholar
  68. 68.
    Lacroix M (2006) Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13:1033–1067.PubMedCrossRefGoogle Scholar
  69. 69.
    Landys K, Persson S, Kovarik J, Hultborn R, Holmberg E (1998) Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat 49:27–33.PubMedCrossRefGoogle Scholar
  70. 70.
    Lankiewicz S, Rivero BG, Bocher O (2006) Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Mol Biotechnol 34:15–27.PubMedCrossRefGoogle Scholar
  71. 71.
    Lindvall C, Bu W, Williams BO, Li Y (2007) Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev 3:157–168.PubMedCrossRefGoogle Scholar
  72. 72.
    Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217–226.PubMedCrossRefGoogle Scholar
  73. 73.
    Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063–6071.PubMedCrossRefGoogle Scholar
  74. 74.
    Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial–mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67:9066–9076.PubMedCrossRefGoogle Scholar
  75. 75.
    Lugo TG, Braun S, Cote RJ, Pantel K, Rusch V (2003) Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol 21:2609–2615.PubMedCrossRefGoogle Scholar
  76. 76.
    Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC (1999) Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354:197–202.PubMedCrossRefGoogle Scholar
  77. 77.
    Marches R, Scheuermann R, Uhr J (2006) Cancer dormancy: from mice to man. Cell Cycle 5:1772–1778.PubMedCrossRefGoogle Scholar
  78. 78.
    Mecklenburg I, Weckermann D, Zippelius A, Schoberth A, Petersen S, Prang N, Riethmuller G, Kufer P (2007) A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer. J Immunol Methods 323:180–193.PubMedCrossRefGoogle Scholar
  79. 79.
    Mehes G, Luegmayr A, Ambros IM, Ladenstein R, Ambros PF (2001) Combined automatic immunological and molecular cytogenetic analysis allows exact identification and quantification of tumor cells in the bone marrow. Clin Cancer Res 7:1969–1975.PubMedGoogle Scholar
  80. 80.
    Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW, Lane N, Wang J, Uhr J (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103:17361–17365.PubMedCrossRefGoogle Scholar
  81. 81.
    Mizrak D, Brittan M, Alison M (2008) CD133: molecule of the moment. J Pathol 214:3–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Mommers EC, Leonhart AM, von Mensdorff-Pouilly S, Schol DJ, Hilgers J, Meijer CJ, Baak JP, van Diest PJ (1999) Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of the breast. Int J Cancer 84:466–469.PubMedCrossRefGoogle Scholar
  83. 83.
    Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56.PubMedCrossRefGoogle Scholar
  84. 84.
    Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11:3678–3685.PubMedCrossRefGoogle Scholar
  85. 85.
    Naume B, Zhao X, Synnestvedt M, Borgen E, Giercksky Russnes H, Lingjorde OC, Stromberg M, Wiedswang G, Kvalheim G, Karesen R, Nesland JM, Borresen-Dale A-L, Sorlie T (2007) Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 1:160–171.PubMedCrossRefGoogle Scholar
  86. 86.
    Naumov GN, Akslen LA, Folkman J (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5:1779–1787.PubMedCrossRefGoogle Scholar
  87. 87.
    Panabieres C, Vendrell J, Pelle O, Rebillard X, Riethdorf S, Müller V, Fabbro M, Pantel K (2007) Identification of biologically active cancer cells in blood and bone marrow of cancer patients. J Clin Oncol 25:1001.Google Scholar
  88. 88.
    Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456.PubMedCrossRefGoogle Scholar
  89. 89.
    Pantel K, Alix-Panabieres C (2007) The clinical significance of circulating tumor cells. Nat Clin Pract Oncol 4:62–63.PubMedCrossRefGoogle Scholar
  90. 90.
    Pantel K, Cote RJ, Fodstad O (1999) Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91:1113–1124.PubMedCrossRefGoogle Scholar
  91. 91.
    Pantel K, Enzmann T, Kollermann J, Caprano J, Riethmuller G, Kollermann MW (1997) Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer 71:521–525.PubMedCrossRefGoogle Scholar
  92. 92.
    Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmuller G (1991) Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 51:4712–4715.PubMedGoogle Scholar
  93. 93.
    Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419–1424.PubMedCrossRefGoogle Scholar
  94. 94.
    Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Izbicki JR, Riethmuller G (1994) Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3:165–173.PubMedCrossRefGoogle Scholar
  95. 95.
    Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA, Harris A (2001) Identification of MUC1 proteolytic cleavage sites in vivo. Biochem Biophys Res Commun 283:715–720.PubMedCrossRefGoogle Scholar
  96. 96.
    Passlick B, Kubuschok B, Izbicki JR, Thetter O, Pantel K (1999) Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg 68:2053–2058.PubMedCrossRefGoogle Scholar
  97. 97.
    Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253:180–204.PubMedCrossRefGoogle Scholar
  98. 98.
    Pfitzenmaier J, Ellis WJ, Arfman EW, Hawley S, McLaughlin PO, Lange PH, Vessella RL (2006) Telomerase activity in disseminated prostate cancer cells. BJU Int 97:1309–1313.PubMedCrossRefGoogle Scholar
  99. 99.
    Pfitzenmaier J, Ellis WJ, Hawley S, Arfman EW, Klein JR, Lange PH, Vessella RL (2007) The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol 25:214–220.PubMedCrossRefGoogle Scholar
  100. 100.
    Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(–/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777–1785.PubMedCrossRefGoogle Scholar
  101. 101.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672.PubMedCrossRefGoogle Scholar
  102. 102.
    Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, Pouillart P, Thiery JP, Magdelenat H (2004) Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10:1392–1400.PubMedCrossRefGoogle Scholar
  103. 103.
    Pinzani P, Salvadori B, Simi L, Bianchi S, Distante V, Cataliotti L, Pazzagli M, Orlando C (2006) Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 37:711–718.PubMedCrossRefGoogle Scholar
  104. 104.
    Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65:5506–5511.PubMedCrossRefGoogle Scholar
  105. 105.
    Ponti D, Zaffaroni N, Capelli C, Daidone MG (2006) Breast cancer stem cells: an overview. Eur J Cancer 42:1219–1224.PubMedCrossRefGoogle Scholar
  106. 106.
    Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49–54.PubMedCrossRefGoogle Scholar
  107. 107.
    Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J, Ebel S, Janicke F, Sauter G, Pantel K (2004) Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10:3422–3428.PubMedCrossRefGoogle Scholar
  108. 108.
    Riethdorf S, Fritsche, H, Müller, V, Rau, T, Schindlbeck. C, Rack, B, Janni, W, Coith, C, Beck, K, Jänicke, F, Jackson, S, Gornet, T, Cristofanilli, M, Pantel, K (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a multi-center validation study of the CellSearchTM system. Clin Cancer Res 13:920–928.PubMedCrossRefGoogle Scholar
  109. 109.
    Ring A, Smith IE, Dowsett M (2004) Circulating tumour cells in breast cancer. Lancet Oncol 5:79–88.PubMedCrossRefGoogle Scholar
  110. 110.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684.PubMedCrossRefGoogle Scholar
  111. 111.
    Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H, Becker KF (2002) Differential expression of the epithelial–mesenchymal transition regulators Snail, SIP1, and Twist in gastric cancer. Am J Pathol 161:1881–1891.PubMedCrossRefGoogle Scholar
  112. 112.
    Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, Polzer B, Petronio M, Eils R, Klein CA (2005) Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8:227–239.PubMedCrossRefGoogle Scholar
  113. 113.
    Schlimok G, Riethmuller G (1990) Detection, characterization and tumorigenicity of disseminated tumor cells in human bone marrow. Semin Cancer Biol 1: 207–215.PubMedGoogle Scholar
  114. 114.
    Schmidt H, DeAngelis G, Eltze E, Gockel I, Semjonow A, Brandt B (2006) Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 66:8959–8965.PubMedCrossRefGoogle Scholar
  115. 115.
    Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100:7737–7742.PubMedCrossRefGoogle Scholar
  116. 116.
    Schulenburg A, Ulrich-Pur H, Thurnher D, Erovic B, Florian S, Sperr WR, Kalhs P, Marian B, Wrba F, Zielinski CC, Valent P (2006) Neoplastic stem cells: a novel therapeutic target in clinical oncology. Cancer 107:2512–2520.PubMedCrossRefGoogle Scholar
  117. 117.
    Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Jr., Badve S, Nakshatri H (2006) CD44+/CD24– breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59.PubMedCrossRefGoogle Scholar
  118. 118.
    Sienel W, Mecklenburg I, Dango S, Ehrhardt P, Kirschbaum A, Passlick B, Pantel K (2007) Detection of MAGE-A transcripts in bone marrow is an independent prognostic factor in operable non-small-cell lung cancer. Clin Cancer Res 13:3840–3847.PubMedCrossRefGoogle Scholar
  119. 119.
    Solomayer EF, Becker S, Pergola-Becker G, Bachmann R, Kramer B, Vogel U, Neubauer H, Wallwiener D, Huober J, Fehm TN (2006) Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 98:179–184.PubMedCrossRefGoogle Scholar
  120. 120.
    Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7:791–799.PubMedCrossRefGoogle Scholar
  121. 121.
    Symmans WF, Liu J, Knowles DM, Inghirami G (1995) Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 26:210–216.PubMedCrossRefGoogle Scholar
  122. 122.
    Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, Braun S, Oberhoff C, Janicke F, Pantel K (2003) Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res 9:2598–2604.PubMedGoogle Scholar
  123. 123.
    Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453–1457.PubMedCrossRefGoogle Scholar
  124. 124.
    van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038–3043.PubMedCrossRefGoogle Scholar
  125. 125.
    Vessella RL, Pantel K, Mohla S (2007) Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther 6:1496–1504.Google Scholar
  126. 126.
    Vincent-Salomon A, Pierga JY, Couturier J, d’Enghien CD, Nos C, Sigal-Zafrani B, Lae M, Freneaux P, Dieras V, Thiery JP, Sastre-Garau X (2007) HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer 96:654–659.PubMedCrossRefGoogle Scholar
  127. 127.
    Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Brechot C, Paterlini-Brechot P (2000) Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156:57–63.PubMedCrossRefGoogle Scholar
  128. 128.
    Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL (2007) Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 13:5001–5009.PubMedCrossRefGoogle Scholar
  129. 129.
    Wicha MS, Liu S, Dontu G (2006) Cancer stem cells: an old idea – a paradigm shift. Cancer Res 66:1883–1890; discussion 1895–1886.PubMedCrossRefGoogle Scholar
  130. 130.
    Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B (2004) Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10:5342–5348.PubMedCrossRefGoogle Scholar
  131. 131.
    Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland JM, Naume B (2006) Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 118:2013–2019.PubMedCrossRefGoogle Scholar
  132. 132.
    Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B (2003) Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21:3469–3478.PubMedCrossRefGoogle Scholar
  133. 133.
    Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K (2005) Changes in cytoskeletal protein composition indicative of an epithelial–mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11:8006–8014.PubMedCrossRefGoogle Scholar
  134. 134.
    Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir-Bauer S (2007) Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol 107:331–338.PubMedCrossRefGoogle Scholar
  135. 135.
    Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J, Bauer KD (2002) Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 8: 1085–1091.PubMedGoogle Scholar
  136. 136.
    Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, Brakenhoff R, Pantel K (2003) Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63: 5679–5684.PubMedGoogle Scholar
  137. 137.
    Wong NS, Kahn HJ, Zhang L, Oldfield S, Yang LY, Marks A, Trudeau ME (2006) Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat 99: 63–69.PubMedCrossRefGoogle Scholar
  138. 138.
    Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, Brandt B (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12:1715–1720.PubMedCrossRefGoogle Scholar
  139. 139.
    Zach O, Lutz D (2006) Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 18: 48–56.PubMedCrossRefGoogle Scholar
  140. 140.
    Zhou X, Liao J, Hu L, Feng L, Omary MB (1999) Characterization of the major physiologic phosphorylation site of human keratin 19 and its role in filament organization. J Biol Chem 274:12861–12866.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2010

Authors and Affiliations

  • Sabine Riethdorf
    • 1
  • Volkmar Müller
    • 2
  • Catherine Alix-Panabières
    • 3
  • Klaus Pantel
    • 4
  1. 1.Institute of Tumour BiologyUniversity Medical Center Hamburg-EppendorfHamburgGermany
  2. 2.Department of GynecologyUniversity Medical Center Hamburg EppendorfHamburgGermany
  3. 3.Virology Laboratory, Lapeyronie HospitalUniversity Medical Center of MontpellierMontpellierFrance
  4. 4.Institute of Tumour BiologyUniversity Medical Center Hamburg- EppendorfHamburgGermany

Personalised recommendations